Submitted by Administrator on Fri, 29/08/2014 - 13:51
Following years of research by Dr Joseph Cheriyan, Prof Ian Wilkinson, Dr James Rudd, and many others, GlaxoSmithKline (GSK) has announced a new Phase III clinical trial - LATITUDE-TIMI 60 - to test a new losmapimod drug in more than 25,000 patients with acute coronary syndrome.
More information about the contribution of Cambridge researchers is available through Addenbrooke's hospital.
Related publications authored by Cambridge investigators:
Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia. Cheriyan J, Webb AJ, Sarov-Blat L, Elkhawad M, Wallace SM, Mäki-Petäjä KM, Collier DJ, Morgan J, Fang Z, Willette RN, Lepore JJ, Cockcroft JR, Sprecher DL, Wilkinson IB. Circulation. 2011 Feb 8;123(5):515-23.
Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis. Elkhawad M, Rudd JH, Sarov-Blat L, Cai G, Wells R, Davies LC, Collier DJ, Marber MS, Choudhury RP, Fayad ZA, Tawakol A, Gleeson FV, Lepore JJ, Davis B, Willette RN, Wilkinson IB, Sprecher DL, Cheriyan J. JACC Cardiovasc Imaging. 2012 Sep;5(9):911-22.
Safety, tolerability, pharmacokinetics and pharmacodynamics of losmapimod following a single intravenous or oral dose in healthy volunteers. Barbour AM, Sarov-Blat L, Cai G, Fossler MJ, Sprecher DL, Graggaber J, McGeoch AT, Maison J, Cheriyan J. Br J Clin Pharmacol. 2013 Jul;76(1):99-106.
